Novo Nordisk has just announced that their drug liraglutide is extremely effective at inducing weight loss among people suffering from type 2 diabetes. In a 56-week long double-blind phase 3a clinical trial, part of the SCALETM (Satiety and Clinical Adiposity Liraglutide Evidence in...
Novo Nordisk is the star of today's health news right now, because the Food and Drug Administration didn't approve two of their new diabetes drugs as expected. But practically all headlines and articles are focused on one thing: What this means for the value of Novo Nordisk shares. Am I crazy...
Novo Nordisk, a world leader in diabetes care, and the advocacy organization Children with Diabetes, Inc. (CWD) announced a two-year partnership to develop and distribute resources that will help newly diagnosed children with type 1 diabetes adjust to their new lifestyle. Every year...
According to SDI's Pharmaceutical Company Image 2010 study, Novo Nordisk was ranked by endocrinologists as the top company overall. The company was mentioned by 62% of the endocrinologists who participated in the annual study - a substantial increase from last year, when it was mentioned by 52%...
Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved Norditropin® FlexPro® (somatropin [rDNA origin] injection), a pre-filled injection pen to be used by children and adults with growth hormone disorders. It will be available in the second quarter...
Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved Norditropin® FlexPro® (somatropin [rDNA origin] injection), a pre-filled injection pen to be used by children and adults with growth hormone disorders. It will be available in the second quarter...